Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, open-label study in stable patients switched from typical and atypical oral antipsychotics

被引：0
|
作者：
Cetin, M [1 ]
Ebrinc, S [1 ]
Basoglu, C [1 ]
Semiz, UB [1 ]
Gunay, H [1 ]
Iyisoy, MS [1 ]
Ergun, BM [1 ]
Gunes, C [1 ]
Sahan, A [1 ]
Oguz, M [1 ]
Noyan, O [1 ]
机构：
[1] Gulhane Haydarpasa Training Hosp, Dept Psychiat, Istanbul, Turkey
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2005年 / 15卷
关键词：
D O I：
10.1016/S0924-977X(05)80287-1
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S134 / S135
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder
    Lasser, R
    Bossie, CA
    Gharabawi, G
    Eerdekens, M
    Nasrallah, HA
    JOURNAL OF AFFECTIVE DISORDERS, 2004, 83 (2-3) : 263 - 275
  • [32] Efficacy and safety of long-acting risperidone injection after switching from antipsychotics in Chinese patients
    Li, H. F.
    Gu, N. F.
    Zhou, M.
    Jia, F. J.
    Zhao, Z. H.
    Fan, J. X.
    Wang, G.
    Sun, X. L.
    Li, M.
    Zhang, J. B.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 : S405 - S406
  • [33] Treatment of schizophrenia with long-acting injectable risperidone: A 12-month open-label trial of the first long-acting second-generation antipsychotic
    Fleischhacker, WW
    Eerdekens, M
    Karcher, K
    Remington, G
    Llorca, PM
    Chrzanowski, W
    Martin, S
    Gefvert, O
    JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (10) : 1250 - 1257
  • [34] Varenicline for Smoking Cessation in Schizophrenia: Safety and Effectiveness in a 12-Week Open-Label Trial
    Pachas, Gladys N.
    Cather, Corinne
    Pratt, Sarah I.
    Hoeppner, Bettina
    Nino, Johanna
    Carlini, Sara V.
    Achtyes, Eric D.
    Lando, Harry
    Mueser, Kim T.
    Rigotti, Nancy A.
    Goff, Donald C.
    Evins, A. Eden
    JOURNAL OF DUAL DIAGNOSIS, 2012, 8 (02) : 117 - 125
  • [35] Direct switch from atypical antipsychotics to long-acting injectable risperidone in schizophrenia and schizoaffective disorders
    Vauth, R
    Kusters, J
    Braendle, D
    SCHIZOPHRENIA RESEARCH, 2004, 67 (01) : 177 - 177
  • [36] Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial
    Gupta, Bhanu
    Chee, Kok-Seng
    Neo, Li-Qi
    Tang, Charmaine
    Hariram, Jayaraman
    Tan, Geoffrey Chern-Yee
    Verma, Swapna
    Basu, Sutapa
    Appan, Deva-Priya
    Ting, Chan-Chun
    Abdin, Edimansyah
    Lee, Jimmy
    THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2021, 11
  • [37] EFFECTIVENESS OF LONG-ACTING INJECTABLE RISPERIDONE AND ORAL ATYPICAL ANTIPSYCHOTICS IN A 24-MONTHS OBSERVATIONAL STUDY IN ADULT PATIENTS WITH SCHIZOPHRENIA IN GERMANY
    Hargarter, L.
    Fleischmann, J.
    Diels, J.
    Rabinowitz, J.
    Hemels, M.
    Gaudig, M.
    Van Sanden, S.
    Schreiner, A.
    VALUE IN HEALTH, 2011, 14 (07) : A287 - A287
  • [38] Safety results from a 12-week open-label, multicenter study of sodium oxybate in patients with narcolepsy
    Mamelak, M.
    Swick, T.
    Emsellem, H.
    Montplaisir, J.
    Lai, C.
    Black, J.
    JOURNAL OF SLEEP RESEARCH, 2014, 23 : 289 - 289
  • [39] Survey of safety and efficacy of long-acting injectable risperidone in daily practice: An open-label, non-interventional prospective study
    Parellada, E.
    Filippos, K.
    Siurkute, A.
    Don, L.
    Medori, R.
    Lex, A.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 154 - 154
  • [40] SURVEY OF SAFETY AND EFFICACY OF LONG-ACTING INJECTABLE RISPERIDONE IN DAILY PRACTICE: AN OPEN-LABEL, NON-INTERVENTIONAL PROSPECTIVE STUDY
    Parellada, E.
    Kouniakis, F.
    Siurkute, A.
    Schreiner, A.
    Don, L.
    EUROPEAN PSYCHIATRY, 2009, 24
12345